- Home
- Our research
- Reports and Findings
- 2021
- August 2021
Lack of effectiveness of 13-valent pneumococcal conjugate vaccination against pneumococcal carriage density in Papua New Guinean infants
Keywords:
Carriage; Microarray; Papua New Guinea; Pneumococcal conjugate vaccine; Serotype;
Streptococcus pneumoniae
Abstract:
Papua New Guinea (PNG) introduced the 13-valent pneumococcal conjugate vaccine (PCV13) in 2014, with administration at 1, 2, and 3 months of age. PCV13 has reduced or eliminated carriage of vaccine types in populations with low pneumococcal carriage prevalence, carriage density and serotype diversity.
Our Authors
Christopher Blyth
MBBS (Hons) DCH FRACP FRCPA PhD
Director, Wesfarmers Centre of Vaccines and Infectious Diseases; Co-Head, Infectious Diseases Epidemiology, Wesfarmers Centre of Vaccines and Infectious Diseases, Honorary and NHMRC Emerging Leadership Fellow
Email meLea-Ann Kirkham
PhD
Co-Head, Bacterial Respiratory Infectious Disease Group; Microbiology Lead, Wesfarmers Centre of Vaccines & Infectious Diseases